HIV drug saquinavir to get new safety data on label
New safety information has been added to the label for the HIV antiviral drug saquinavir mesylate (Invirase, Genentech), describing potentially life-threatening side effects on the heart when used with ritonavir (Norvir, Abbott Laboratories), another HIV antiviral medication, according to FDA.
New safety information has been added to the label for the HIV antiviral drug saquinavir mesylate (Invirase, Genentech), describing potentially life-threatening side effects on the heart when used with ritonavir (Norvir, Abbott Laboratories), another HIV antiviral medication, according to FDA.
In February 2010, the agency warned patients and healthcare professionals that when used together, saquinavir and ritonavir could cause prolongation of the QT and PR intervals - indicators of abnormal heart rhythm activity seen on an electrocardiogram. FDA will also require a medication guide for patients who use saquinavir, describing potential risks.
Patients with underlying heart conditions or those that have existing heart rate or rhythm problems are at greatest risk, the agency said.
FDA made the decision to require additional safety information to assure that providers and patients are adequately informed of the risks, an agency spokeswoman told Formulary.
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More
